Price trends of reimbursed oncological drugs in Switzerland in 2005-2019: A descriptive analysis.
Increasing oncological treatment costs are a major global concern with the risk of entailing two-tiered health care. Among cost determining factors is the price of individual drugs. In recognition of the central role of this factor, we present a comprehensive overview of the development of monthly p...
Enregistré dans:
Auteurs principaux: | Yael Rachamin, Christoph Jakob Ackermann, Oliver Senn, Thomas Grischott |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Public Library of Science (PLoS)
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/7cceb14eaa2541c6b333e1e614f3fbb9 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Price trends of reimbursed oncological drugs in Switzerland in 2005–2019: A descriptive analysis
par: Yael Rachamin, et autres
Publié: (2021) -
Change in Colorectal Cancer Tests Submitted for Reimbursement in Switzerland 2012–2018: Evidence from Claims Data of a Large Insurance
par: Rémi Schneider, et autres
Publié: (2021) -
The Impasse on Overall Survival in Oncology Reimbursement Decision-Making: How Can We Resolve This?
par: Lux MP, et autres
Publié: (2021) -
A Comparative Analysis of Pricing and Reimbursement of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Europe
par: Khadidja Abdallah, et autres
Publié: (2021) -
Geography of medication reimbursements in Belgium: an exploratory analysis
par: Sonia Trabelsi, et autres
Publié: (2021)